Similarly, Koch et al. established an EpCAM+ CTC line derived from breast cancer [112] and Faugeroux et al. generated CTC-derived explant models by using EpCAM+ CTCs isolated from blood samples of patients with castration-resistant prostate cancer (Figure 2) [113]. Here, EPCAM is linked to prostate cancer.